Sign In
Buy BETRF
$0.0471
+0.0041 (+9.53%)
At Close: Jun 03, 2026
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference
08:00am, Thursday, 21'st Apr 2022
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focu
BetterLife says BETR-001 demonstrates strong anti-depressant activity in preclinical models of depression
01:03pm, Wednesday, 06'th Apr 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF), a biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, revealed that it has obtained additio
BetterLife Pharma says preclinical data has confirmed bioavailability of BETR-001
04:57pm, Wednesday, 16'th Mar 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced it had confirmed the bioavailability of its lead compound BETR-001 in the brain tissue and plasma of treated mice. BETR-001 is a non-hallucinoge
BetterLife Pharma says LSD analog BETR-001 promotes structural neural plasticity in preclinical model
09:32am, Tuesday, 15'th Feb 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has obtained positive results from a preclinical neural plasticity study of BETR-001 in cortical rat neurons, as part of its collaboration with th
BetterLife Pharma launches its new corporate website
09:10am, Thursday, 10'th Feb 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has launched its newly-designed website, which can be accessed at abetterlifepharma.com. The company said its new corporate website bet
BetterLife receives positive FDA response to its pre-IND application for major depressive disorder treatment with BETR-001
08:52am, Thursday, 20'th Jan 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has received a positive written response from the US Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application
BetterLife Pharma announces positive results from its in vivo oral bioavailability study on BETR-001 in beagle dogs
10:29am, Tuesday, 18'th Jan 2022
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK) study on BETR-001 in beagle dogs
BetterLife Pharma welcomes key new investor group for its Altum Pharmaceuticals subsidiary
11:15am, Wednesday, 22'nd Dec 2021
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that its subsidiary, Altum Pharmaceuticals Inc has obtained non-dilutive financing from a key investor. The subsidiary has inked an agree
BetterLife Pharma reports positive pre-clinical data on TD-0148A to treat depression
08:53am, Thursday, 09'th Dec 2021
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) reported positive findings from pre-clinical studies on mice, which showed the therapeutic potential of its 2-bromo-LSD (TD-0148A) candidate as an anti-de
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that its subsidiary Altum Pharmaceuticals Inc and Pontificia Universidad Católica de Chile have successfully completed the Phase 1 portion of P
BetterLife Pharma has a promising pipeline of psychedelic products, a coronavirus nebulizer and AP-001 cream
02:44pm, Wednesday, 24'th Nov 2021
Three compelling and differentiated assets Potential coronavirus treatment AP-003's Phase 2 trial to start in 2Q 2021 Management team led by veteran entrepreneur CEO Dr Ahmad Doroudian What BetterLife
BetterLife Pharma says pharmacology data on second-generation LSD derivative confirms its projected non-hallucinogenic property
09:13am, Tuesday, 16'th Nov 2021
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has obtained the first set of behavioral animal pharmacology data for its lead compound, 2-bromo-LSD (TD-0148A), in collaboration with t
BetterLife obtains TD-0148A pharmacology data confirming its activity in receptors implicated in depression and neuropathic pain
09:47am, Thursday, 04'th Nov 2021
BetterLife Pharma Inc. (CSE:BETR, OTCQB:BETRF), a biotech company focused on the development of treatments for mental disorders, revealed that it has obtained the first set of neurological receptor fu
BetterLife Pharma Inc. revealed early positive in vitro results of its proprietary inhaled interferon alpha-2b product, AP-00, from a preclinical study at Dr Stephen Barr's Lab at the ImPaKT Facility,
BetterLife Pharma obtains TD-0148A neurological receptor binding data for IND-enabling pharmacology studies
09:51am, Wednesday, 29'th Sep 2021
BetterLife Pharma Inc., a biotech company focused on the development of cutting-edge treatments for mental disorders, revealed that it has obtained its first set of neurological receptor binding data
